{
  "name" : "dacemirror.sci-hub.se_journal-article_954f08e90c87317a23816d7aa096084c_lin2018.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Protective role of nano-selenium-enriched Bifidobacterium longum in delaying the onset of streptozotocin-induced diabetes",
    "authors" : [ "Yan Lin", "Yongzhe Ren", "Yan Zhang", "Junjie Zhou", "Feng Zhou", "Quan Zhao", "Genxing Xu", "Zichun Hua" ],
    "emails" : [ "zchua@nju.edu.cn", "genxingxu@nju.edu.cn" ],
    "sections" : [ {
      "heading" : null,
      "text" : "rsos.royalsocietypublishing.org\nResearch Cite this article: Lin Y, Ren Y, Zhang Y, Zhou J, Zhou F, Zhao Q, Xu G, Hua Z. 2018 Protective role\nof nano-selenium-enriched Bifidobacterium\nlongum in delaying the onset of streptozotocin-\ninduced diabetes. R. Soc. open sci. 5: 181156. http://dx.doi.org/10.1098/rsos.181156\nReceived: 15 July 2018\nAccepted: 8 November 2018\nSubject Category: Biology (whole organism)\nSubject Areas: biotechnology\nKeywords: Nano-Se-B. longum, STZ-induced diabetes,\nprotective effect\nAuthors for correspondence: Zichun Hua\ne-mail: zchua@nju.edu.cn\nGenxing Xu\ne-mail: genxingxu@nju.edu.cn\n& 2018 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original author and source are credited.\nProtective role of nano-selenium-enriched Bifidobacterium longum in delaying the onset of streptozotocin-induced diabetes Yan Lin1,2, Yongzhe Ren1, Yan Zhang3,4, Junjie Zhou1,\nFeng Zhou1, Quan Zhao1, Genxing Xu1,3,4\nand Zichun Hua1,4,5\n1School of Life Sciences, State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, Jiangsu, People’s Republic of China 2School of Nursing, Xinxiang Medical University, Xinxiang 453000, Henan, People’s Republic of China 3Nanjing Industrial Innovation Center for Pharmaceutical Biotechnology, Nanjing Genrecom Laboratories, Ltd., Nanjing 210031, Jiangsu, People’s Republic of China 4Changzhou High-Tech Research Institute of Nanjing University, Jiangsu Target Pharma Laboratories Inc., Changzhou 213164, Jiangsu, People’s Republic of China 5Shenzhen Research Institute, Nanjing University, Shenzhen 518057, Guangdong, People’s Republic of China\nZH, 0000-0001-7962-0402\nBifidobacterium longum (B. longum) could accumulate Selenium (Se) and nano-Se in the form of Se-B. longum and Nano-Se-B. longum, respectively. In this study, the effect of Nano-Se-B. longum in diabetic mice was evaluated. Physiological and metabolic parameters such as blood glucose, body weight, serum insulin level, intraperitoneal glucose tolerance test (IPGTT), food intake, water consumption and urine output were evaluated. The expression of insulin signalling pathway-related proteins was evaluated by western blotting. Haematoxylin and eosin (H&E) was used for histological examination of the liver, pancreas and kidney sections. Creatinine levels in serum (SCr) and blood urea nitrogen (BUN) were measured. Nano-Se-B. longum was the best in terms of delaying the onset of diabetes. Nano-Se-B. longum decreased blood glucose and body weight compared with those noted for the model group. IPGTT, food intake, water consumption and urine output significantly increased and serum insulin levels significantly decreased in the model group compared with those in all the Nano-Se-B. longum-treated mice.\nrsos.royalsocietypu 2 Histological results showed that the Nano-Se-B. longum-treated mice were better than the model group mice in terms of pathological changes. The expression of insulin signalling pathway-related proteins was upregulated in the Nano-Se-B. longum-treated groups. A significant increase in SCr and BUN levels was noted in the model group. This study for the first time reported the dose-dependent preventive effect of Nano-Se-B. longum on the onset of diabetes and renal damage. The mechanism may be related to changes in insulin signalling.\nblishing.org R.Soc.open sci.5:181156 1. Introduction B. longum, a Gram-positive anaerobic bacterium present in the human gastrointestinal tract, protects the host against viral infections [1,2]. Bifidobacteria are used as probiotics for supporting digestion in many countries [3]. Our previous studies showed that B. longum has anti-cancer effects on solid liver cancer [4–9]. To date, numerous studies have demonstrated the benefits of probiotics in managing metabolic disorders including diabetes. Currently, research groups are focusing on this novel concept.\nSe, an essential micronutrient for the health of both humans and animals, is actively involved in animal physiology via various selenoproteins [10]. Se supplementation was reported to decrease plasma glucose levels in diabetic rats [11] and humans [12]. Se has also been proven to induce a sustained improvement of glucose homeostasis in diabetic individuals to regulate vital metabolic processes such as glycolysis and gluconeogenesis [13]. The administration of selenium at suitable doses was shown to improve kidney impairments of diabetic kidney disease (DKD) by changing the lipid contents, restoring the ordered structure of the lipids and membrane dynamics [14]. Treatment of diabetic rats with a combination of insulin and Se was effective in controlling blood glucose [15]. However, recent epidemiological studies indicated supranutritional selenium intake and high plasma selenium levels as possible risk factors for the development of type 2 diabetes [16]. Numerous studies have reported the organification of Se through a microorganism fermentation technique for the production of organic Se compounds with higher biological activities and lower toxicity than those of inorganic Se. Organic Se can be absorbed and used rapidly, making it a focus area in recent years [17]. Nano-Se accumulated in B. longum existed in the form of selenoproteins and the main component of the organic Se was SeMet. It attracts even more attention thanks to its high bioavailability and lower toxicity. Nano-Se was found to have a hepatoprotective effect, a tumour inhibitory effect, and to improve the immune function of mice [18,19]. These selenoproteins play a preventive role in some degenerative conditions including cancer, inflammatory diseases, neurological diseases, ageing, infertility and infections through specific cellular pathways [20]. Although the mechanisms underlying the anti-diabetic activities of Se are not fully understood, some of the proposed mechanisms include antioxidant protection and stimulation of the immune system. In our previous studies [4,9], we found that B. longum could accumulate Se in the form of Se-B. longum, affecting tumour growth and immune function in tumour-bearing mice.\nPrevious studies showed that dietary supplementation with multiple probiotic strains, including Lactobacillus acidophilus, L. casei, L. rhamnosus, L. bulgaricus, B. breve, B. longum and S. thermophilus, has been shown to prevent elevations in fasting plasma glucose in diabetic patients [21]. Oral administration of Bifidobacterium spp. lowers serum glucose, enhances the expression of proteins involved in the insulin signalling pathway and improves adipokine profile in diabetic mice [22]. A recent study focused on the anti-diabetic effect of Bifidobacterium spp. and its molecular mechanism [23]. However, the protective effects of Nano-Se-B. longum in a high glucose model have not yet been studied in detail. The effects of Nano-Se-B. longum on renal function are also unknown. In this study, wild-type B. longum (WT B. longum), Se-B. longum and Nano-Se-B. longum were used to compare their protective effect on the onset of streptozotocin (STZ)-induced diabetes.\nTherefore, we examined whether oral administration of Nano-Se-B. longum can delay the onset of STZ-induced diabetes, possibly by affecting the insulin signalling pathway. It was also investigated whether Nano-Se-B. longum ameliorates the damage to renal function caused by high glucose levels.\n2. Material and methods 2.1. Nanoparticle formulation and size measurements Nanoparticles were prepared as described earlier [19]. Briefly, 1 ml of 25 mM sodium selenite (Sangon Biotech Co., Ltd., Shanghai, China), 4 ml of 25 mM reduced glutathione (Sangon Biotech Co., Ltd.,\nrsos.royalsocietypublishing.org 3\nShanghai, China), and 20 mg bovine serum albumin (Sangon Biotech Co., Ltd., Shanghai, China) were mixed. The pH was adjusted to 7.2 with sodium hydroxide, which led to the formation of red nano-Se and oxidized glutathione (GSSG). The red solution was dialysed against double distilled water for 96 h with the water changing every 24 h to separate GSSG from Nano-Se under magnetic stirring. The final solution containing Nano-Se and BSA was subjected to centrifugation at 13 000 r.p.m. for 10 min. The pellet thus recovered was subjected to washing by its re-suspension in deionized water followed by centrifugation at 13 000 r.p.m. for 10 min, to remove possible organic contamination present in the nanoparticles. Finally, the pellet was freeze-dried using a lyophilizer and stored at room temperature. Size measurements were performed using a Zetasizer Nano-ZSE (Malvern Instruments, Malvern, UK) with Zetasizer Software v. 7.12. The results are reported as the average of 40–44 measurements+ s.d.\nR.Soc.open sci.5:181156 2.2. Preparation of WT B. longum, Se-B. longum and nano-Se-B. longum strain for administration\nB. longum NQ-1501 was obtained from the Inner Mongolia Shuangqi Medical Industry Corporation (Inner Mongolia, China) and anaerobically cultured at 378C in TPY medium. Se enrichment of B. longum was performed according to the previously established protocol [8]. Briefly, sodium selenite was purchased from Shanghai LuYuan Fine Chemical Factory, weighed, and dissolved in 200 ml TPY medium at a concentration of 25 mg ml21. Nano red elemental Se was dissolved in 200 ml TPY medium at 5 mg ml21. B. longum, Se-B. longum and Nano-Se-B. longum were cultivated overnight in TPY medium anaerobically. This overnight culture was diluted 1 : 25 in TPY medium and cultivated at 378C until the OD600 reached about 0.2. The cultured strains were collected and then washed three times with 5% glucose saline by centrifugation at 3500 g for 5 min at 48C. The collected strains were resuspended in 0.1 ml of 13% milk just prior to use. Live bacteria were prepared daily for administration to each mouse.\n2.3. Animals The mice (aged between 4 and 5 weeks (w)) were maintained in a specific pathogen-free animal facility under a 12 h light–dark cycle at an ambient temperature of 218C. They were provided with water and foods ad libitum.\n2.4. Induction of experimental diabetes Male mice (C57BL/6) aged 4–5 w were purchased from Nanjing model animal research center of Nanjing University and diabetes was induced with STZ (Merck, Darmstadt, Germany) as previously described [24]. Briefly, after overnight fasting (deprived of food for 12 h and allowed free access to water), diabetes was induced in mice by i.p. injection of STZ dissolved in 0.1 M cold citrate buffer (pH ¼ 4.5) at a dose of 50 mg kg21 body weight for 5 consecutive days. Control mice were injected with citrate buffer alone. Diabetes was confirmed by the determination of fasting blood glucose level on the third-day post-final administration of STZ. Mice with fasting blood glucose levels greater than or equal to 11.1 mM were considered diabetic. Blood glucose levels were monitored every week after diabetes was confirmed using the glucose meter (Sinocare Inc., Changsha, Hunan, China).\n2.5. Effect of WT B. longum, Se-B. longum and nano-Se-B. longum on glucose level The effects of WT B. longum, Se-B. longum and Nano-Se-B. longum on glucose levels of STZ-induced diabetes were determined. The prepared viable organism suspension in 0.1 ml was administered by gavage once a day for 4 w simultaneously. Fifty mice were randomly divided into five groups: Control group—normal; Model group—STZ-induced diabetic mice; WT B. longum group, Se-B. longum group and Nano-Se-B. longum group—STZ-induced diabetic mice treated with 3 1010 bacteria kg21, respectively. Strain prepared in 0.1 ml of viable microorganism suspension was administered by gavage once a day for 4 w simultaneously. Diabetes was induced in mice by i.p. injection of STZ for 5 consecutive days on the 25th day after strain administered.\nrsos.royalsocietypublishing.org R.Soc.ope\n4 2.6. Dose-dependent effect of nano-Se-B. longum Nano-Se-B. longum prepared in 0.1 ml of viable microorganism suspension was administered by gavage once a day for 4 w simultaneously. Overall, we assessed 60 mice in the six experiments. There were six groups as follows:\nControl group: normal; Model group: STZ-induced diabetic mice; Low dose group: STZ-induced diabetic mice treated with 7.5 109 bacteria kg21 Nano-Se-B. longum (treated); Middle dose group: STZ-induced diabetic mice treated with 1.5 1010 bacteria kg21 Nano-Se-B. longum (treated); High dose group: STZ-induced diabetic mice treated with 3 1010 bacteria kg21 Nano-Se-B. longum (treated); Toxicity test group: normal mice treated with 3 1010 bacteria kg21 Nano-Se-B. longum\nn sci.5:181156\n2.7. Physiological assessment and metabolic analysis The protective effect of Nano-Se-B. longum in mice was studied at different doses administered for 4 w. Nano-Se-B. longum was administered during the injection of STZ. Blood glucose levels were monitored 3 days to 8 w after the final STZ injection using a glucometer via the caudal vein. Serum insulin levels were determined using Rat/Mouse Insulin ELISA (Millipore Corp, Billerica, MA, USA) at the end of the experiment. Food intake, water consumption and urine output were measured after the mice were placed in metabolic cages overnight. At the eighth week after final STZ injection, eyeball blood was collected and the mice were euthanized. At the end of the experiment, the levels of SCr and BUN were also determined using the assay kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, Jiangsu, China). IPGTT was performed in mice on the seventh week after final STZ injection (n ¼ 3). For IPGTT, mice were subjected to an overnight fast followed by an intraperitoneal glucose injection (1.0 g kg21). Blood glucose was measured at 0, 15, 30, 60, and 90 min after the injection.\n2.8. Western blotting analysis The liver samples were isolated from all the mice and then snap-frozen in liquid N2 for subsequent protein extractions. The collected tissue samples were lysed in ice-cold lysis buffer (20 mM Tris– HCl (pH ¼ 7.5), 150 mM NaCl, 1% Triton-X 100, 1 mM EDTA) and a protein inhibitor cocktail for 30 min. The supernatant was boiled with Laemmli sample buffer for SDS-PAGE. The following antibodies were used: anti-IRS1, anti-phospho-IRS1 (pIRS1), anti-GSK-3b, anti-phospho-GSK-3b (pGSK-3b), anti-AKT and anti-phospho-AKT (pAKT) (Thr308) (Cell Signaling Technology, Beverly, MA); anti-b-actin monoclonal antibody, anti-a-tubulin and anti-GAPDH were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, Delaware, USA). Goat anti-rabbit IgG and goat anti-mouse IgG were from Jackson ImmunoResearch Europe Ltd. The band densities were quantified by using Image J program.\n2.9. Histological analysis To observe the morphological changes of the liver, pancreas and kidney, H&E staining was carried out as described before [25]. In brief, the liver, pancreas and kidney tissues were fixed in 4% paraformaldehyde for 16–24 h and transferred to ethanol. Then, the samples were embedded in paraffin and sectioned at 5 mm, followed by H&E staining.\n2.10. Statistical analysis Data are presented as means+SEM. The difference between two groups was analysed by a two-tailed Student’s t-test using Prism software (GraphPad, San Diego, CA). Values were considered statistically significant at p , 0.05.\n25\n20\n15\nfa st\nin g\nbl oo\nd gl\nuc os\ne (m\nm ol\nl– 1 )\n10\n5\n0 –1 w 1 w 2 w\n##\n### ###\n### ### ### ###\n###\n**\n**** **\n** ** *\n*\ntime after final STZ injection (week) 3 w 4 w 5 w 6 w 7 w 8 w\nnormal\nmodel\nNano-Se-B. longum\nSe-B. longum\nWT B. longum\nFigure 1. The effects of WT B. longum, Se-B. longum and Nano-Se-B. longum on glucose. Blood glucose measurement of the mice during the fasting course at 1 w before STZ injection and at 1 – 8 w after final STZ injection. Data are presented as means+ s.e.m. (n ¼ 10 per group). Statistical significance was assessed by two-tailed Student’s t-test. (##p , 0.01, ###p , 0.001 compared with normal group; *p , 0.05, **p , 0.01 compared with the model group).\nrsos.royalsocietypublishing.org R.Soc.open sci.5:181156 5\n3. Results 3.1. Effects of WT B. longum, Se-B. longum and nano-Se-B. longum on glucose levels\nof STZ-induced diabetes Nano-Se-B. longum exhibited the best effect on fasting blood glucose levels (figure 1). Thus, Nano-Se-B. longum was chosen for further studies.\n3.2. Effects of nano-Se-B. longum on physiological and metabolic parameters Blood glucose testing is the gold standard for the subclinical diagnosis of diabetes. Nano-Se-B. longum-treated mice exhibited notably lower fasting blood glucose levels (figure 2a) and higher body weight (figure 2b) than model mice. Because glucose homeostasis is mainly regulated by insulin, we also detected its serum concentration (n ¼ 6). Fasting insulin levels were higher in Nano-Se-B. longum-treated mice (figure 2c) than in model mice. Twenty-four-hour food intake, water intake and urine volume were measured (n ¼ 10) and found to be decreased with an increase in the dosage of Nano-Se-B. longum (figure 3). In the IPGTT assay (n ¼ 3), the glucose levels decreased significantly in model group mice (figure 4), indicating an improved glucose clearance after Nano-Se-B. longum intervention in a dose-dependent manner.\n3.3. Effects of nano-Se-B. longum on morphological changes in the liver and pancreas Histological analysis of the liver and pancreas by H&E staining showed a notable difference between NanoSe-B. longum-treated and control mice. As shown in figure 5a, there were no obviously harmful changes in the control mice and toxicity test group mice. A small amount of fat vacuoles was observed in part of the pancreatic section in the model, low, middle, and high dose groups (black arrow). Small amounts of inflammatory cells were only visible in the tissue in the model group (red arrow). With the increase in the dosage of Nano-Se-B. longum, the degree of lesion decreased gradually. As shown in figure 5b, no obviously harmful changes in the control mice and toxicity test group were noted. The hepatic cells were edematous and the cytoplasm was loose in the tissue (black arrow) in the STZ-treated groups, while the degree of lesion decreased gradually with an increase in the dosage of Nano-Se-B. longum. Small amounts of inflammatory cells were visible in the tissue (red arrow) in the model group and the degree of infiltrated inflammatory cells decreased with an increase in the dosage of Nano-Se-B. longum (red arrow). Overall, the progression of liver and pancreas pathological damage was slowed after Nano-Se-B. longum treatment.\n3.4. Nano-Se-B. longum improved liver insulin signalling sensitivity To investigate the molecular mechanisms underlying hypoglycaemia, we studied the insulin signalling pathway, which plays a critical role in glucose homeostasis. The mice were assessed for the presence of pIRS1, pGSK-3b and pAkt (Thr308). As shown in figure 6a,c, the expression of pIRS-1 and pAkt\nincreased significantly in the liver from the treatment group compared with that in the control mice. pGSK-3b levels decreased markedly in the trial group compared with that in control mice (figure 6b). The expression of insulin signalling pathway proteins was upregulated, which showed that Nano-Se-B. longum improved liver insulin signalling sensitivity.\n3.5. Protective role on renal function The influence of Nano-Se-B. longum on the kidney is attributable to its effects on the glomeruli. With the increase in Nano-Se-B. longum dosage, mesentery cell hyperplasia and glomerulus atrophy decreased gradually (black arrow) (figure 7a). Nano-Se-B. longum markedly decreased the levels of BUN and SCr in serum in STZ-induced mice compared to control mice (figure 7b,c). These data suggest that Nano-Se-B. longum may improve the renal function damaged by diabetes.\n4. Discussion In this study, the effects of WT B. longum, Se-B. longum and Nano-Se-B. longum on glucose were measured. The results showed that Nano-Se-B. longum was the best with respect to the protective effect on high blood glucose. Normal mice were treated with the maximum dose of Nano-Se-B. longum and no\nsignificant difference was observed compared to normal mice. Sudin Bhattacharya research group had synthesized and characterized Nano-Se and found its chemoprotective (CP) activity against CPinduced hepatotoxicity, pulmonary and genotoxicity in normal Swiss albino mice [19,26] and its antitumour efficacy in the tumour-bearing Swiss albino mice [18]. The anti-genotoxic effect of Nano-Se might be due to its antioxidant and cytoprotective activity. Now, Nano-Se-B. longum showed its safety and protective effect in STZ-induced diabetes. We have expanded the functions of Nano-Se, providing further understanding and insight. Some studies found that the restorative effect of selenium on\nnormal model low dose group middle dose group high dose grouptoxicity test group\n(b)\n(a)\nFigure 5. Effect of Nano-Se-B. longum on the pancreas and liver morphological changes (H&E stain; 20 10). Histopathological observations made on the pancreas (a) and liver (b) of experimental groups of mice and the photomicrographs presented are the representatives of the eight mice used in each group. Representative images are shown, at a magnification of 200.\nno rm\nal\nmo de\nl\nlow do\nse gr\nou p\nmi dd\nle do\nse gr\nou p\nhig h d\nos e g\nro up\ntox ici\nty tes\nt g ro\nup\nno rm\nal\nmo de\nl\nlow do\nse gr\nou p\nmi dd\nle do\nse gr\nou p\nhig h d\nos e g\nro up\ntox ici\nty tes\nt g ro\nup\n1.5 ##\n### * *\n*1.0\n0.5pI R\nS1 /I\nR S1\n2.5\n2.0\n1.5\n1.0\n0.5\n0\npG SK\n-3 b/\nG SK\n-3 b\n0 pIRS1 pGSK-3b\nGSK-3bIRS1 170 KD 180 KD\n46 KD 46 KD\n(b)\nno rm\nal\nmo de\nl\nlow do\nse gr\nou p\nmi dd\nle do\nse gr\nou p\nhig h d\nos e g\nro up\ntox ici\nty tes\nt g ro\nup\n60 KD 60 KD\n# *\n1.5\n1.0\n0.5\n0\npA K\nT (T\nhr 30\n8) /A\nK T\npAKT (Thr308)\nAKT\n(c)\n(a)\nFigure 6. The analysis of the insulin signalling pathway. Liver pIRS1 (a), pGSK-3b (b) and pAKT (c) protein levels were measured by western blot analysis, which were normalized to IRS1, GSK-3b and AKT, respectively. Data were shown as mean s.e.m. (three mice per group). Statistical significance was assessed by two-tailed Student’s t-test. (#p , 0.05, ##p , 0.01, ###p , 0.001, compared with normal group; *p , 0.05 compared with the model group).\nrsos.royalsocietypublishing.org R.Soc.open sci.5:181156 8\ndiabetes is predominantly related to the antioxidant and insulin-like properties of selenium [14]. However, further studies are required to investigate the precise mechanisms involved in the protective effect of Nano-Se-B. longum against diabetes.\nThe insulin signalling pathway controls glucose transport in liver cells. Insulin binds to insulin receptors on the surfaces of target cells. This binding activates insulin receptor beta (IR-b), and then\nactivates IRS1, thereby recruiting phosphatidylinositol 3-kinase (PI3 K) to this location. An important target of PI3 K in liver cells is Akt/PKB, which has a key function in glucose uptake [27]. Previous studies have shown that pIRS1 and pAkt upregulation may have improved glucose uptake by the reduced plasma glucose levels [28]. Oral administration of Nano-Se-B. longum may give rise to elevated plasma selenium levels by enhanced hepatic secretion of selenoproteins, which may enhance insulin-induced signal transduction [16]. Therefore, we assessed the effects of Nano-Se-B. longum administration on insulin signalling pathways. In our study, Nano-Se-B. longum increased the levels of pIRS1 and pAkt proteins and decreased pGSK-3b in diabetic mice. We can reasonably speculate that an increase in the selenoproteins induced by Nano-Se-B. longum treatment enhanced insulin sensitivity by promoting the insulin signalling pathway.\nDiabetes mellitus can cause serious health problems including macrovascular and microvascular complications [29]. One of these is injuries to the kidney tissue that result in renal dysfunction [30]. Eight weeks after STZ diabetes induction, some indexes of renal damage such as an increase in BUN were noted [31]. There is a large amount of evidence to support the recovery effects of selenium, at suitable doses, on the cell membrane of diabetic kidneys. The beneficial effect of selenium on renal lesions can be explained with its insulin-like effect [32]. Recently, Feride Severcan et al. [14] also showed the efficiency of a low dose (1 mmol kg21) of selenium administration in the prevention of diabetes-related complications in kidneys. We also investigated the renoprotective effect of Nano-Se-B. longum in STZ-induced mice. Nano-Se-B. longum can decrease renal dysfunction by lowering BUN and SCr. Our experiments in Nano-Se-B. longum-treated and STZ-induced diabetes mice revealed that Nano-Se-B. longum exerts a protective role in delaying the onset of STZ-induced diabetes as well as renal function. However, further studies are required to investigate the precise mechanisms involved in the renoprotective effect.\nrsos. 10\nOur findings may facilitate the understanding of the novel effects of Nano-Se-B. longum and suggest a newly recognized benefit of Nano-Se-B. longum in diabetic mice. This may provide a novel, feasible, economic protection approach for diabetes, thus deserving further investigation and development.\nroyalsocietypublishing.org R.Soc.open sci.5:181156 5. Conclusion In this study, we demonstrated that oral administration of Nano-Se-B. longum can delay the onset of STZinduced diabetes, possibly via its effect on the insulin signalling pathway. It was also investigated that Nano-Se-B. longum ameliorates the damage of renal function caused by high glucose levels. Our findings may facilitate the understanding of the novel effects of Nano-Se-B. longum and suggest a newly recognized benefit of Nano-Se-B. longum in diabetic mice.\nEthics. All animal studies were performed according to approved Animal Care and Use Committee protocols of Nanjing University in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Data accessibility. Our data are deposited at Dryad Digital Repository: (http://dx.doi.org/10.5061/dryad.v4g40ms) [33]. Authors’ contributions. Y.L., Y.R. and Y.Z. carried out the molecular laboratory work, participated in data analysis, carried out the preparation of nano-Se and participated in the design of the study and drafted the manuscript; F.Z. carried out the statistical analyses; J.Z. collected field data; Z.H., G.X. and Q.Z. conceived of the study, designed the study, coordinated the study and helped draft the manuscript; Z.H. provided the funding for the study. All authors gave final approval for publication. Competing interests. We have no competing interests. Funding. This study was supported in part by grants from the National Key R&D Research Program by Ministry of Science and Technology (2017YFA0506002), and the Chinese National Natural Sciences Foundation (81630092, 81773099, 81570790, 81573338) and Shenzhen Science and Technology Innovation Committee (JCYJ20160331152141936), Shenzhen Peacock Plan (KQTD20140630165057031). Acknowledgements. We warmly thank Dr Mingxing Wang for the guide of the animal experiments.\nReferences\n1. Yen PK. 2003 Probiotics and prebiotics for bowel\nhealth. Geriatr. Nurs. 24, 192 – 193. 2. Picard C, Fioramonti J, Francois A, Robinson T,\nNeant F, Matuchansky C. 2005 Review article: Bifidobacteria as probiotic agents – physiological effects and clinical benefits. Aliment. Pharmacol. Ther. 22, 495 – 512. (doi:10.1111/j.1365-2036.2005.02615.x) 3. Chen JJ, Wang R, Li XF, Wang RL. 2011 Bifidobacterium longum supplementation improved high-fat-fed-induced metabolic syndrome and promoted intestinal Reg I gene expression. Exp. Biol. Med. 236, 823 – 831. (doi:10.1258/ebm.2011.010399) 4. Yin Y, Wang RR, Wang Y, Wang JJ, Xu GX. 2014 Preparation of selenium-enriched Bifidobacterium longum and its effect on tumor growth and immune function of tumor-bearing mice. Asian Pac. J. Cancer Prev. 15, 3681 – 3686. (doi: 10.7314/APJCP.2014.15.8.3681) 5. Li X, Fu GF, Fan YR, Liu WH, Liu XJ, Wang JJ, Xu GX. 2003 Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther. 10, 105 – 111. (doi:10.1038/sj.cgt.7700530) 6. Xu YF, Zhu LP, Hu B, Fu GF, Zhang HY, Wang JJ, Xu GX. 2007 A new expression plasmid in Bifidobacterium longum as a delivery system of endostatin for cancer gene therapy. Cancer Gene Ther. 14, 151 – 157. (doi:10.1038/sj.cgt. 7701003) 7. Zhu LP, Yin Y, Xing J, Li C, Kou L, Hu B, Wu ZW, Wang JJ, Xu GX. 2009 Therapeutic efficacy of\nBifidobacterium longum-mediated human granulocyte colony-stimulating factor and/or endostatin combined with cyclophosphamide in mouse-transplanted tumors. Cancer Sci. 100, 1986 – 1990. (doi:10.1111/j.1349-7006.2009. 01275.x) 8. Fu GF, Li X, Hou YY, Fan YR, Liu WH, Xu GX. 2005 Bifidobacterium longum as an oral delivery system of endostatin for gene therapy on solid liver cancer. Cancer Gene Ther. 12, 133 – 140. (doi:10.1038/sj.cgt.7700758) 9. Li C, Chen X, Kou L, Hu B, Zhu LP, Fan YR, Wu ZW, Wang JJ, Xu GX. 2010 SeleniumBifidobacterium longum as a delivery system of endostatin for inhibition of pathogenic bacteria and selective regression of solid tumor. Exp. Ther. Med. 1, 129 – 135. (doi:10.3892/etm_ 00000022) 10. Perottoni J, Rodrigues OE, Paixao MW, Zeni G, Lobato LP, Braga AL, Rocha JB, Emanuelli T. 2004 Renal and hepatic ALA-D activity and selected oxidative stress parameters of rats exposed to inorganic mercury and organoselenium compounds. Food Chem. Toxicol. 42, 17 – 28. (doi:10.1016/j.fct.2003. 08.002) 11. Douillet C, Tabib A, Bost M, Accominotti M, Borson-Chazot F, Ciavatti M. 1996 A selenium supplement associated or not with vitamin E delays early renal lesions in experimental diabetes in rats. Exp. Biol. Med. 211, 323 – 331. (doi:10.3181/00379727-211-43976) 12. Wang WC, Makela AL, Nanto V, Makela P. 1995 Serum selenium levels in diabetic children. A\nfollowup study during selenium-enriched agricultural fertilization in Finland. Biol. Trace Elem. Res. 47, 355 – 364. (doi:10.1007/ BF02790138)\n13. Becker DJ, Reul B, Ozcelikay AT, Buchet JP, Henquin JC, Brichard SM. 1996 Oral selenate improves glucose homeostasis and partly reverses abnormal expression of liver glycolytic and gluconeogenic enzymes in diabetic rats. Diabetologia 39, 3 – 11. (doi:10.1007/ BF00400407) 14. Gurbanov R, Bilgin M, Severcan F. 2016 Restoring effect of selenium on the molecular content, structure and fluidity of diabetic rat kidney brush border cell membrane. Biochim. Biophys. Acta 1858, 845 – 854. (doi:10.1016/j. bbamem.2016.02.001) 15. Xu TJ, Yuan BX, Zou YM, Zang WJ. 2010 The effect of insulin in combination with selenium on blood glucose and GLUT4 expression in the cardiac muscle of streptozotocin-induced diabetic rats. Fundam. Clin. Pharmacol. 24, 199 – 204. (doi:10.1111/j.1472-8206.2009.00715.x) 16. Steinbrenner H, Speckmann B, Pinto A, Sies H. 2011 High selenium intake and increased diabetes risk: experimental evidence for interplay between selenium and carbohydrate metabolism. J. Clin. Biochem. Nutr. 48, 40 – 45. (doi:10.3164/jcbn.11-002FR) 17. Zhang Y, Okeke BC, Frankenberger Jr WT. 2008 Bacterial reduction of selenate to elemental selenium utilizing molasses as a carbon source. Bioresour. Technol. 99, 1267 – 1273. (doi:10. 1016/j.biortech.2007.02.048)\nrsos.royalsocietypublishing.org R.Soc.open sci.5:181156 11\n18. Bhattacharjee A, Basu A, Biswas J, Sen T,\nBhattacharya S. 2017 Chemoprotective and chemosensitizing properties of selenium nanoparticle (Nano-Se) during adjuvant therapy with cyclophosphamide in tumor-bearing mice. Mol. Cell. Biochem. 424, 13 – 33. (doi:10.1007/ s11010-016-2839-2) 19. Bhattacharjee A, Basu A, Ghosh P, Biswas J, Bhattacharya S. 2014 Protective effect of Selenium nanoparticle against cyclophosphamide induced hepatotoxicity and genotoxicity in Swiss albino mice. J. Biomater. Appl. 29, 303 – 317. (doi:10.1177/0885328214523323) 20. Kaur R, Sandhu HS. 2008 In vivo changes in antioxidant system and protective role of selenium in chlorpyrifos-induced subchronic toxicity in Bubalus bubalis. Environ. Toxicol. Pharmacol. 26, 45 – 48. (doi:10.1016/j.etap.2008.01.004) 21. Asemi Z, Zare Z, Shakeri H, Sabihi SS, Esmaillzadeh A. 2013 Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. Ann. Nutr. Metab. 63, 1 – 9. (doi:10.1159/000349922) 22. Le, TK et al. 2015 Bifidobacterium species lower serum glucose, increase expressions of insulin signaling proteins, and improve adipokine profile in diabetic mice. Biomed. Res. 36, 63 – 70. (doi:10.2220/biomedres.36.63)\n23. Hara N, Alkanani AK, Ir D, Robertson CE, Wagner BD, Frank DN, Zipris D. 2012 Prevention of virus-induced type 1 diabetes with antibiotic therapy. J. Immunol. 189, 3805 – 3814. (doi:10. 4049/jimmunol.1201257) 24. Rai PK, Jaiswal D, Mehta S, Rai DK, Sharma B, Watal G. 2010 Effect of Curcuma longa freeze dried rhizome powder with milk in STZ induced diabetic rats. Ind. J. Clin. Biochem. 25, 175 – 181. (doi:10.1007/s12291-010-0032-z) 25. Jacobetz MA et al. 2013 Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 62, 112 – 120. (doi:10.1136/gutjnl-2012-302529) 26. Bhattacharjee A, Basu A, Biswas J, Bhattacharya S. 2015 Nano-Se attenuates cyclophosphamideinduced pulmonary injury through modulation of oxidative stress and DNA damage in Swiss albino mice. Mol. Cell. Biochem. 405, 243 – 256. (doi:10.1007/s11010-015-2415-1) 27. Bryant NJ, Govers R, James DE. 2002 Regulated transport of the glucose transporter GLUT4. Nat. Rev. Mol. Cell Biol. 3, 267 – 277. (doi:10.1038/ nrm782) 28. Lin PP et al. 2013 Probiotic-fermented purple sweet potato yogurt activates compensatory IGFIR/PI3 K/Akt survival pathways and attenuates cardiac apoptosis in the hearts of spontaneously\nhypertensive rats. Int. J. Mol. Med. 32, 1319 – 1328. (doi:10.3892/ijmm.2013.1524)\n29. Rheinberger M, Boger CA. 2014 [Diabetic nephropathy: new insights into diagnosis, prevention and treatment]. Dtsch Med. Wochenschr. 139, 704 – 706. (doi:10.1055/s0034-1369841) 30. Eid S, Maalouf R, Jaffa AA, Nassif J, Hamdy A, Rashid A, Ziyadeh FN, Eid AA. 2013 20-HETE and EETs in diabetic nephropathy: a novel mechanistic pathway. PLoS One. 8, e70029. (doi:10.1371/ journal.pone.0070029) 31. Parvizi MR, Parviz M, Tavangar SM, Soltani N, Kadkhodaee M, Seifi B, Azizi Y, Keshavarz M. 2014 Protective effect of magnesium on renal function in STZ-induced diabetic rats. J. Diab. Metab. Disord. 13, 84. (doi:10.1186/s40200-014-0084-3) 32. Stackhouse S, Miller PL, Park SK, Meyer TW. 1990 Reversal of glomerular hyperfiltration and renal hypertrophy by blood glucose normalization in diabetic rats. Diabetes 39, 989 – 995. (doi:10.2337/diab.39.8.989) 33. Lin Y, Ren YZ, Zhang Y, Zhou JJ, Zhou F, Zhao Q, Xu GX, Hua ZC. 2018 Data from: protective role of nano-selenium-enriched Bifidobacterium longum in delaying the onset of streptozotocininduced diabetes. Dryad Digital Repository. (doi:10.5061/dryad.v4g40ms)"
    } ],
    "references" : [ {
      "title" : "Probiotics and prebiotics for bowel health",
      "author" : [ "Yen PK" ],
      "venue" : "Geriatr. Nurs. 24,",
      "citeRegEx" : "1",
      "shortCiteRegEx" : "1",
      "year" : 2003
    }, {
      "title" : "Review article: Bifidobacteria as probiotic agents – physiological effects and clinical benefits",
      "author" : [ "C Picard", "J Fioramonti", "A Francois", "T Robinson", "F Neant", "C. Matuchansky" ],
      "venue" : "Aliment. Pharmacol. Ther. 22,",
      "citeRegEx" : "2",
      "shortCiteRegEx" : "2",
      "year" : 2005
    }, {
      "title" : "Bifidobacterium longum supplementation improved high-fat-fed-induced metabolic syndrome and promoted intestinal Reg I gene expression",
      "author" : [ "JJ Chen", "R Wang", "XF Li", "RL. Wang" ],
      "venue" : "Exp. Biol. Med. 236,",
      "citeRegEx" : "3",
      "shortCiteRegEx" : "3",
      "year" : 2011
    }, {
      "title" : "Preparation of selenium-enriched Bifidobacterium longum and its effect on tumor growth and immune function of tumor-bearing mice",
      "author" : [ "Y Yin", "RR Wang", "Y Wang", "JJ Wang", "GX. Xu" ],
      "venue" : "Asian Pac. J. Cancer Prev",
      "citeRegEx" : "4",
      "shortCiteRegEx" : "4",
      "year" : 2014
    }, {
      "title" : "selective inhibitor of angiogenesis and hypoxic tumor growth",
      "author" : [ "X Li", "GF Fu", "YR Fan", "WH Liu", "XJ Liu", "JJ Wang", "therapy Xu GX. 2003 Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene" ],
      "venue" : "Cancer Gene Ther. 10, 105 – 111.",
      "citeRegEx" : "5",
      "shortCiteRegEx" : null,
      "year" : 0
    }, {
      "title" : "A new expression plasmid in Bifidobacterium longum as a delivery system of endostatin for cancer gene therapy",
      "author" : [ "YF Xu", "LP Zhu", "B Hu", "GF Fu", "HY Zhang", "JJ Wang", "GX. Xu" ],
      "venue" : "Cancer Gene Ther",
      "citeRegEx" : "6",
      "shortCiteRegEx" : "6",
      "year" : 2007
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "longum, a Gram-positive anaerobic bacterium present in the human gastrointestinal tract, protects the host against viral infections [1,2].",
      "startOffset" : 132,
      "endOffset" : 137
    }, {
      "referenceID" : 1,
      "context" : "longum, a Gram-positive anaerobic bacterium present in the human gastrointestinal tract, protects the host against viral infections [1,2].",
      "startOffset" : 132,
      "endOffset" : 137
    }, {
      "referenceID" : 2,
      "context" : "Bifidobacteria are used as probiotics for supporting digestion in many countries [3].",
      "startOffset" : 81,
      "endOffset" : 84
    }, {
      "referenceID" : 3,
      "context" : "In our previous studies [4,9], we found that B.",
      "startOffset" : 24,
      "endOffset" : 29
    } ],
    "year" : 2018,
    "abstractText" : "School of Life Sciences, State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, Jiangsu, People’s Republic of China School of Nursing, Xinxiang Medical University, Xinxiang 453000, Henan, People’s Republic of China Nanjing Industrial Innovation Center for Pharmaceutical Biotechnology, Nanjing Genrecom Laboratories, Ltd., Nanjing 210031, Jiangsu, People’s Republic of China Changzhou High-Tech Research Institute of Nanjing University, Jiangsu Target Pharma Laboratories Inc., Changzhou 213164, Jiangsu, People’s Republic of China Shenzhen Research Institute, Nanjing University, Shenzhen 518057, Guangdong, People’s Republic of China",
    "creator" : "Arbortext Advanced Print Publisher 9.1.520/W"
  }
}